Live Breaking News & Updates on Horizon Therapeutics Public Limited Company Stock Exchange

Stay updated with breaking news from Horizon therapeutics public limited company stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT

Two patients will share their real-world experience living with TED and being. | June 5, 2023 ....

Olmsted County , United States , Jeffreyw Sherman , Malini Gupta , Duke University Health System , European Group On Grave Orbitopathy , Drug Administration , Endocrine Society , Horizon Therapeutics , Thyroid Eye Disease , Safety Results , Placebo Controlled Multicenter Trial , Oral Presentation , Multicenter Trial , Hearing Related Issues Associated , Grave Disease , Hearing Related Adverse Events , Teprotumumab Oncology Clinical Trials , Teprotumumab Pooled Efficacy , European Study Sites Participating , Inactive Thyroid Eye Disease Patient Journey , Eye Disease , Early Diagnosis , Duke University Health , Treatment Experience , Exhibit Hall ,

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks. | June 1, 2023 ....

United States , Neuroimmunol Neuroinflamm , Orhan Aktas , Kristina Patterson , Department Of Neurology , Exchange Commission , Horizon Therapeutics , Expanded Disability Status Scale , Medical Faculty , Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Full Prescribing Information , United States Securities , Accessed April , Scler Relat , Horizon Therapeutics Public Limited Company Stock Exchange , Press Release , Mosd Hznp Ie00bqpvqz61 ,

Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome

Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types

Patients with moderate-to-severe systemic disease activity treated with. | May 31, 2023 ....

South Hall , Argyll And Bute , United Kingdom , Elizabethhz Thompson , Newcastle University , European Congress , Company Phase , Clinical Research Institute , Horizon Therapeutics , Moderate To Severe Systemic Disease , Syndrome Disease Activity Index , Concept Study , Session Room , Syndrome Patient Reported Index , Biomarker Analysis , Reduces Blood Biomarkers , Poster Hall , Syndrome Trial , Horizon Therapeutics Public Limited Company Stock Exchange , Press Release , Reated Hznp Ie00bqpvqz61 ,

Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology

Phase 2 results for dazodalibep in Sjögren’s syndrome to be presented on June 1, 11:35-11:45 a.m. CEST and June 3, 9:35-9:45 a.m. CEST

Planned presentations illustrate. | May 23, 2023 ....

South Hall , Argyll And Bute , United Kingdom , Chiara Baldini , Elizabethhz Thompson , Department Of Clinical , Clinical Research Institute , University Of Pisa , Newcastle University , European Congress , Horizon Therapeutics , Experimental Medicine , Rheumatology Unit , Poster Hall , Heart Failure , Full Prescribing Information , Horizon Therapeutics Public Limited Company Stock Exchange , Press Release , Resentations Hznp Ie00bqpvqz61 ,

Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen

Horizon Therapeutics plc today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company:

“This acquisition. | May 16, 2023 ....

Horizon Therapeutics , Horizon Therapeutics Public Limited Company Stock Exchange , Press Release , He Hznp Ie00bqpvqz61 ,